Regulatory Pathway Design & Advisory
Specialist regulatory counsel for FDA, EU MDR, and global agency submissions. From pre-submission strategy through clinical evidence design, submission preparation, and post-market compliance.
Regulatory Strategy as a Competitive Advantage
Regulatory strategy is not a compliance exercise — it is a material determinant of speed to market, competitive positioning, and ultimately enterprise value. The right regulatory pathway, executed with precision, can compress a product's time to US or EU market by 12–24 months relative to a suboptimal approach.
Innekto Incorporated's regulatory team approaches each engagement with a first-principles analysis: what is the optimal pathway given this device's characteristics, clinical evidence base, and commercial objectives? We do not apply templated approaches to complex situations.
Our advisors have directly prepared and defended submissions before FDA and worked with EU Notified Bodies across multiple device categories — experience that cannot be replicated by generalist consultants reading the same guidance documents.
Figures represent aggregate firm experience. Individual client outcomes will vary based on device complexity and regulatory circumstances.
FDA Market Authorisation Pathways
| Pathway | Code | Device Class | Typical Timeline | Key Feature |
|---|---|---|---|---|
| Premarket Notification | 510(k) | Class I / II | 6–12 months | Demonstrates that a device is substantially equivalent to a legally marketed pre… |
| Premarket Approval | PMA | Class III | 18–36 months | The most stringent FDA pathway, requiring valid scientific evidence demonstratin… |
| De Novo Classification | De Novo | Class I / II (Novel) | 12–18 months | For novel low-to-moderate risk devices without a valid predicate. Creates a new … |
| Investigational Device Exemption | IDE | All Classes | 3–6 months approval | Permits investigational use of a device in a clinical study to collect safety an… |
Additional Regulatory Frameworks
All Regulatory Engagements
FDA 510(k) Clearance for Class II Intimate Care Therapeutic
FDA 510(k) clearance obtained with no additional information requests issued. The pre-submission engagement validated the predicate strategy and produced a favourable FDA response, enabling the client to file with high confidence. Clearance was achieved within target timelines, and the client reached US market launch readiness immediately upon notification.
Regulatory Strategy Development for Gastrointestinal Therapeutic Program
A comprehensive multi-jurisdiction regulatory roadmap was delivered, providing a defined development pathway from IND through NDA/BLA. The strategy identified the US indication with the strongest probability-of-approval profile and the most capital-efficient clinical data package. The resulting framework was directly integrated into investor communications and enabled the client to structure a capital raise to fund the Phase 2 program.
US Market Expansion Strategy for Nutraceutical and Cosmetic Portfolio
The client achieved regulatory clarity across the full product portfolio. Each line was assigned a defensible classification, compliant label claims, and a defined US entry pathway. The phased roadmap enabled immediate launch of the priority product cohort and provided a scalable framework for the remainder of the portfolio. The engagement restored distributor confidence and re-opened commercial negotiations on a compliance-ready basis.
PMA Strategy for Novel Class III Cardiac Device
The pre-IDE application was accepted by FDA with no clinical hold issued and a single minor administrative query. The clinical protocol was finalised and IRB-approved within six months of engagement commencement. EU MDR technical file structure was accepted by a designated notified body, with the clinical evaluation timeline aligned with the IDE study data generation. The defined regulatory roadmap was directly incorporated into the Series B investor materials and supported successful closure of the financing round.
Saudi Market Entry Strategy for Digital Health Platform
SFDA digital health notification was obtained within eight months of engagement commencement. A strategic platform partnership and licensing agreement was executed with a leading Saudi integrated healthcare group, providing access to a network of hospitals and primary care centres across the Kingdom. Data residency modifications were implemented within the agreed timeline, enabling compliant commercial deployment. Platform revenue in the first year of Saudi operations exceeded the client's internal projections, with contracted expansion to two additional GCC markets initiated in Year 2.
Discuss Your Regulatory Requirements
Contact our regulatory team for a pathway assessment and strategy discussion.
The information presented on this page is intended for institutional counterparties and professional investors only. All references to target returns, yield strategies, and projected outcomes represent forward-looking estimates subject to material market, credit, liquidity, and operational risks. Past performance is not indicative of future results. Nothing herein constitutes an offer to buy or sell securities or investment products.